Clinical Trials

A clinical trial is a research study that tries to find better ways to prevent, screen for, diagnose, or treat a disease like bladder cancer.  They are an essential part of cancer research.  Trials may provide possible treatment alternatives to patients who have not had success with standard and approved therapies.

Why you consider a clinical trial to treat your bladder cancer

Here are several reasons bladder cancer patients should consider participating in a clinical trial:

  • Access to cutting-edge bladder cancer treatments: By participating, you may access effective or advanced treatment options that are not yet available to everyone. These treatments may have better results than the standard of care or existing therapies and could improve their chances of successful outcomes.
  • Contribute to medical advancement: Bladder cancer patients play a vital role in helping researchers understand the disease better. Clinical trials help develop new therapies, and enhance existing ones, which can benefit future generations who may be diagnosed with bladder cancer.
  • Close monitoring and care: Patients in clinical trials receive close medical supervision and monitoring. This level of attention can lead to better management of side effects and complications, ensuring the patient’s safety and well-being throughout the trial.
  • Hope for a cure or extended life: For some bladder cancer patients, clinical trials offer the hope of finding a cure or extending their life when conventional treatments have not been effective.

Bladder cancer patients should talk with their healthcare team, to determine whether a clinical trial is an option for their specific situation. They should carefully weigh the potential benefits and risks, ensuring they make an informed decision about their treatment plan.

You can search for a clinical trial below by bladder cancer disease state, state of residence and you can also look for trials nearest to you.

About Clinical Trials

To help find trials near you, you need to allow BCAN to access your location
Ok

Title State Sponsoring Organization
Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome Multi-State Albert Einstein College of Medicine
Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients With Muscle-Invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations Multi-State Alliance for Clinical Trials in Oncology
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering Minnesota Intima Bioscience, Inc.
Avelumab and Radiation in Muscle-Invasive Bladder Cancer Massachusetts Dana-Farber Cancer Institute
Cretostimogene Grenadenorepvec Given in Patients With Non-Muscular Invasive Bladder Cancer, Unresponsive to BCG Multi-State CG Oncology, Inc.
Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER – (ADAPT-BLADDER) HCRN GU16-243 Multi-State Noah Hahn, M.D.
Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer Maryland National Cancer Institute (NCI)
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy Multi-State Nanobiotix
Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment Multi-State Memorial Sloan Kettering Cancer Center

Learn more about the different phases clinical trials here.